DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS The FIL-ROUGE trial studied 503 adults with previously untreated Hodgkin lymphoma.
New research has provided evidence that intensified ABVD can enhance outcomes for patients with untreated Hodgkin lymphoma. The findings were presented at the International Conference on Malignant Lymphoma 2023 and contribute to ongoing discussions on optimal treatment regimens.
Key Points:
- Patients in the trial were treated with either dose-dense or dose-intense ABVD (ABVDDD-DI) or PET-adapted ABVD.
- 3-year progression-free survival (PFS) and event-free survival (EFS) rates were 87% and 81% respectively for ABVDDD-DI, compared to 73% and 67% respectively for PET-adapted ABVD.
- Complete response (CR) rate was higher with ABVDDD-DI than with PET-adapted treatment at the end of the trial—94% versus 85%.
- Primary refractory disease rate was 4% in the ABVDDD-DI arm and 12% in the PET-adapted treatment arm.
Additional Points:
- The 3-year overall survival rate was 99% in the ABVDDD-DI arm and 98% in the PET-adapted treatment arm.
- Grade 3-4 adverse events occurred in 70% of ABVDDD-DI patients and 57% of PET-adapted treatment patients.
- Serious adverse events were experienced by 25% of ABVDDD-DI patients and 16% of PET-adapted treatment patients.
Conclusion:
- Intensified ABVD was found to improve PFS and EFS rates, and had a higher CR rate in the FIL-ROUGE trial. However, further data on mid-term and long-term toxicity are required.
Hematology/Oncology Latest Posts
- ASCO 2026 Late Breakers: What We’re Watching and What It Means
- Tazemetostat Withdrawn Over Secondary Primary Cancer Risk
- The Addition of PARP Inhibition to Androgen Receptor Pathway Inhibition in Metastatic Hormone-Sensitive Prostate Cancer
- Making Sense of the 2026 Centers for Medicare and Medicaid Services (CMS) Radiation Oncology Treatment Delivery Codes: Historical Context and Practical Applications for Clinicians
“The results of this trial suggest there may be no need for early PET-adapted therapy and a limited need for radiotherapy in this patient population.”
Antonio Pinto, MD
Study Presenter
Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”
Naples, Italy
